Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity.
Details
Download: 1-s2.0-S2589004223003656-main.pdf (2923.55 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_A5198D931AE8
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity.
Journal
iScience
ISSN
2589-0042 (Electronic)
ISSN-L
2589-0042
Publication state
Published
Issued date
21/04/2023
Peer-reviewed
Oui
Volume
26
Number
4
Pages
106288
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Abstract
Antigen selection and prioritization represent crucial determinants of vaccines' efficacy. Here, we compare two personalized dendritic cell-based vaccination strategies using whole-tumor lysate or neoantigens. Data in mouse and in cancer patients demonstrate that peptide vaccines using neoantigens predicted on the sole basis of in silico peptide-major histocompatibility complex (MHC) binding affinity underperform relative to whole-tumor-lysate vaccines. In contrast, effective in vitro peptide-MHC binding affinity and peptide immunogenicity significantly improve the prioritization of tumor-rejecting neoepitopes and result in more efficacious vaccines.
Keywords
Cancer, Immunity, Molecular medicine
Pubmed
Web of science
Open Access
Yes
Create date
24/03/2023 12:11
Last modification date
09/12/2023 7:02